Genenta Science S.p.A.: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Apr 1, 2026 and accepted by EDGAR at Mar 31, 2026, 17:56 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2025-01-01 to 2025-12-31 | EUR 2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −EUR 6.6m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2025-01-01 to 2025-12-31 | −EUR 6.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −EUR 0.33 | us-gaap:EarningsPerShareDiluted |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 19,710,187 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −EUR 6.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | EUR 7.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2025-12-31 | EUR 30.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | EUR 31.9m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | EUR 2.1m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2025-12-31 | EUR 21.8m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-12-31 | 23,432,183 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001493152-26-014387. Last ingested by Listed: Nov 2, 2026, 06:07 ET. Listed shows no prices and gives no investment advice.